Sorafenib is a multi-kinase inhibitor that targets several receptor tyrosine kinases including, VEGFR-1, -2 and -3 and PDGFR-β, and serine threonine kinases including, Raf-1 and B-Raf, all shown to be involved in neovascularization and tumor progression [23,24]. Here, FLT1 is linked to neoplasm.